close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.38 +0.39 (+2.79%)
Official Closing Price Updated: 4:10 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Journey Medical Touts Positive PK Data For Bacterial Infection Candidate ↗
 
Via Benzinga
News headline image
Dr. Reddy’s Successfully Completes Phase 1 Study of DRL_TC, a Proposed Biosimilar of Tocilizumab
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug ↗
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
News headline image
World Economic Forum Recognises Dr. Reddy’s Hyderabad Factory as Part of its Global Lighthouse Network
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Intercept Settles Ocaliva Litigation With Reddy's Lab ↗
 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces the Launch of Lenalidomide Capsules in the U.S. With Two of Six Strengths Eligible for First-to-market, 180-day Exclusivity
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Is Sanofi A Buy, Despite Recent Stumbles?
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions. 
Via MarketBeat
Topics Intellectual Property
News headline image
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
India Based Pharma Companies In Race To Buy Athenex, Shares Surge ↗
 
Via Benzinga
News headline image
Eton Pharma Shares Tick Higher After Offloading Hospital Products ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning! We're starting off the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
From Dr. Reddy’s Laboratories Ltd. 500124
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
From Aurigene Discovery Technologies Limited
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Acquisition of an Injectable Product Portfolio from Eton Pharma
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Pemetrexed for Injection USP, in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Positive Phase 2 Results Of SciSparc's Cannabinoid-Based Drug Candidate May Offer Some New Hope To Tourette Syndrome Patients ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
European Cannabis Q1 2022 Quarterly Update ↗
Just like the United States’ state-by-state movement, Europe is moving country-by-country toward providing access to cannabis. 
Via Talk Markets
News headline image
Dr. Reddy's Laboratories Announces the Launch of Posaconazole Delayed-Release Tablets in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories & MediCane Health To Launch Medical Cannabis Products In Germany ↗
Dr. Reddy's Laboratories Ltd.  (NYSE: RDY)  and MediCane Health Inc. announced the launch of its medical cannabis product in Germany. 
Via Benzinga
News headline image
Dr. Reddy's Laboratories and MediCane Health Announce the Launch of Medical Cannabis Products in Germany
From MediCane Health Inc.
Via Business Wire
News headline image
Flood Helping Ukraine ↗
Emerging markets are gaining as mature markets look risky. 
Via Talk Markets
News headline image
Up On Bad News ↗
Despite the plane crash in China, Boeing's stock is up today. 
Via Talk Markets
News headline image
The Ruble Is Rubble ↗
MSCI says Russian companies are 
Via Talk Markets
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today